We expand, promote, facilitate multidisciplinary activities in HIV/AIDS research.

HU CFAR HOME | CORE SERVICES | RESEARCH PRIORITIES

WE ARE BUILDING A NEW WEBSITE!

Help us design an easy-to-navigate website by completing this brief Treejack study!

SPOTLIGHTING Parmit Kumar Singh

Dr. Parmit Kumar Singh joined Dr. Alan Engelman’s laboratory at the Center for Virology and Immunology within the Dana-Farber Cancer Institute, Harvard Medical School in November 2016. He's interested in understanding the mechanism of splicing-based HIV-1 integration.

Dr. Singh is a current recipient of an HU CFAR Developmental award and an NIH CFAR Supplement award.

Read about his journey in HIV research, the challenges and mentors he found along the way, his future goals and current advice to early-stage HIV investigators, and the findings from his recent publication (Singh, P.K., G.J. Bedwell, and A.N. Engelman, Spatial and Genomic Correlates of HIV-1 Integration Site Targeting. Cells, 2022. 11(4).)

Q&A with Parmit!

Parmit Kumar Singh, Ph.D.  
Research Associate in Medicine, Dana-Farber Cancer Institute, Harvard Medical School
@meioticdrrive

HU CFAR FUNDING OPPORTUNITIES

request for proposals  
2 UNIQUE FUNDING OPPORTUNITIES

HU CFAR FUNDING OPPORTUNITIES
NIH Launches Clinical Trial of Three mRNA HIV Vaccines

HHS Announces Nearly $44 Million to Strengthen Mental Health and Substance Use Services for Populations at Risk for or Living with HIV/AIDS

CDC Issues NOFO to Strengthen Syringe Services Programs
Last week, CDC announced a new Notice of Funding Opportunity (NOFO) for Strengthening Syringe Services Programs (CDC-RFA-PS22-2208).

New PrEP Guidelines (April 20, 2022 / 12-1pm ET)
In this webinar, Dr. Kevin Ard will provide updated guidance related to PrEP, informed by new PrEP guidelines and the FDA approval of injectable PrEP.

Register to attend the April 20 Webinar

This session will have 1.0 credit available through the AAFP. Check out the topic page, Pre-Exposure Prophylaxis (PrEP), from NEAETC’s online HIV Resource Library.

The California National Primate Research Center (CNPRC) Pilot Program invites Letters of Intent for pilot project proposals to support basic and translational research using nonhuman primates (rhesus macaque and titi monkeys) for the 2022-2023 funding period. Questions about the CNPRC Pilot Program may be emailed to the Associate Director of Research lmiller@ucdavis.edu
The deadline for Letters of Intent is April 15, 2022

Duke University’s Department of Population Health Sciences Summer Institute for early- to mid-career researchers, healthcare professionals, students, and trainees.
June 13 – June 24, 2022 (Virtual program)

COVID-19 Resurgence, Other Infections and the Loss of Healthcare for >3 Million People (IDSE, Infectious Disease Special Edition)
Modifying the Vaginal Microbiome: Insights may lead to more effective treatments for bacterial vaginosis, improve women's health (The study was supported in part by the Harvard University Center for AIDS Research)

TWITTER MATTER

On the eve of its 10th birthday, oral PrEP remains out of reach for most who could benefit globally—and without structural changes to simplify access, injectables will suffer the same fate. New from me & @douglaskrakower on the urgency of making PrEP easy:

thelancet.com
Making PrEP easy
As pre-exposure prophylaxis (PrEP) approaches its tenth birthday, there is much to celebrate. In populations with hi...
Current Funding Opportunities

NIH Funding Opportunities

Enhancing HIV Reservoir Susceptibility to Elimination
RFA-AI-22-025 (R01 Clinical Trial Not Allowed)

Development of HIV Broadly Neutralizing Antibody Susceptibility Assays
RFA-AI-22-022 (R61/R33 Clinical Trial Not Allowed)

Advancing HIV/AIDS Research at the Intersection of Oral and Mental Health
RFA-DE-23-002 (R01 Clinical Trial Not Allowed)
RFA-DE-23-003 (R21 Clinical Trial Not Allowed)

Biomarker Signatures of TB Infection in Young Children With and Without HIV
RFA-AI-22-015 (R01 Clinical Trial Not Allowed)

Advancing Communication Strategies to Support Future HIV Vaccine Use
RFA-MH-22-170 (R01 Clinical Trial Optional)
RFA-MH-22-171 (R21 Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data
RFA-DA-22-037 (R01 Clinical Trial Optional)
RFA-DA-22-038 (R21 Clinical Trial Optional)

NIH Notices Pertaining to HIV/AIDS

NOSI: Research to Prevent Drug Use, Misuse and Addiction
NOT-DA-23-001

National Institute on Aging (NIA) Notice of Special Interest (Administrative Supplements for HIV/AIDS and Aging Research)
NOT-AG-22-014

Other Useful Links:

- View all Fogarty funding opportunities
- Search all NIH funding opportunities and notices
- Subscribe to NIH Guide for Grants and Contracts weekly emails
- @NIAIDFunding
- NIAID Opportunities & Announcements
- NIH Funding Opportunities and Notices (for week ending April 1, 2022)
- NIAID Funding News - Edition February 16, 2022
- NIH COVID-19 Open Funding Opportunities

HU CFAR Acknowledgements

This newsletter is a publication of the Harvard University Center for AIDS Research (HU CFAR), an NIH funded program (P30 AI060354) which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NIDCR, NHLBI, NIDA, NIMH, NIA, NIDDK, NINR, NIMHD, FIC, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
To learn more about core services available to the Harvard HIV research community and for information about the HU CFAR, please visit https://cfar.globalhealth.harvard.edu/

Click here to view past newsletters!

Harvard University Center for AIDS Research